atezolizumab

Description: Atezolizumab (also known as MPDL3280A; trade name: Tecentriq) is a novel and selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1). In May 2016 FDA granted accelerated approval to atezolizumab for locally advanced or metastatic urothelial carcinoma treatment after failure of cisplatin-based chemotherapy.3 The confirmatory trial (to convert the accelerated approval into a full approval) failed to achieve its primary endpoint of overall survival. In October 2016, FDA approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.

References: Semin Oncol. 2015 Jun; 42(3):484-7.